MiniMed Group Earnings Call Transcripts
Fiscal Year 2027
-
Q1 delivered 16% organic revenue growth, driven by strong U.S. and international performance, new product launches, and expanding recurring revenue streams. Fiscal 2027 guidance was raised, with margin expansion expected as separation costs decline and new products ramp globally.
Fiscal Year 2026
-
The company is accelerating growth with a robust innovation pipeline, including new launches like Flex and Fit, and a differentiated closed-loop algorithm, Vivera, targeting a 2027 launch. Strong commercial scale, disciplined financial management, and a stable, incentivized team underpin durable growth and expanding global presence.
-
U.S. growth accelerated in Q1 due to new product launches, with Fit patch pump and Vivera algorithm set to expand the market, especially among Type 2 patients. Manufacturing and pharmacy strategies are in place to support upcoming launches, while international growth remains robust. Guidance and profitability targets are reaffirmed.
-
AID systems are driving market growth, with new product launches and a robust pipeline supporting both U.S. and global expansion. The company leverages an integrated technology platform, direct commercial presence, and disciplined financial strategy to maintain competitive advantage and deliver sustained growth.
-
Record fiscal 2026 revenue surpassed $3 billion, with 8% organic growth and strong international performance. New product launches and pipeline advancements underpin a 10% organic growth outlook for FY 2027, with EBITDA margin expansion expected.